Literature DB >> 1280481

Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death.

M A Brach1, S deVos, H J Gruss, F Herrmann.   

Abstract

In the absence of appropriate stimuli, polymorphonuclear neutrophils (PMN) undergo programmed cell death (PCD), also termed apoptosis. We show that granulocyte-macrophage colony-stimulating factor (GM-CSF), but not the chemotactic factors formyl-methionyl-leucyl-phenylalanine (FMLP), recombinant human (rh) C5a, transforming growth factor (TGF)-beta, and interleukin-8 (IL-8), or other cytokines including IL-3, IL-4, IL-6, and G-CSF, maintains viability of PMN in culture by preventing these cells from undergoing PCD. Prevention from PCD by GM-CSF was associated with induction of RNA and protein synthesis in PMN. Inhibition of RNA and protein synthesis by actinomycin-D and cycloheximide impeded the protection of apoptosis by GM-CSF. Similarly, neutralization of GM-CSF biologic activity by a specific antiserum abrogated GM-CSF-mediated inhibition of PCD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280481

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7.

Authors:  J Liu; T Akahoshi; T Sasahana; H Kitasato; R Namai; T Sasaki; M Inoue; H Kondo
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Effects of staphylococcal enterotoxins on human neutrophil functions and apoptosis.

Authors:  D A Moulding; C Walter; C A Hart; S W Edwards
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis.

Authors:  D Girard; R Paquin; A D Beaulieu
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 4.  Peculiarities of cell death mechanisms in neutrophils.

Authors:  B Geering; H-U Simon
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

5.  Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia.

Authors:  P A Courtney; A D Crockard; K Williamson; A E Irvine; R J Kennedy; A L Bell
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

6.  Novel role of regulatory T cells in limiting early neutrophil responses in skin.

Authors:  Hannah Richards; Anwen Williams; Emma Jones; James Hindley; Andrew Godkin; Anna Katharina Simon; Awen Gallimore
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

7.  The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.

Authors:  Peter G Barlow; Yuexin Li; Thomas S Wilkinson; Dawn M E Bowdish; Y Elaine Lau; Celine Cosseau; Christopher Haslett; A John Simpson; Robert E W Hancock; Donald J Davidson
Journal:  J Leukoc Biol       Date:  2006-06-22       Impact factor: 4.962

8.  HIV-1-infected peripheral blood mononuclear cells enhance neutrophil survival and HLA-DR expression via increased production of GM-CSF: implications for HIV-1 infection.

Authors:  Jun Fu; Beverly E Sha; Larry L Thomas
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

9.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  Spontaneous and Fas-induced apoptotic cell death in aged neutrophils.

Authors:  C Tortorella; G Piazzolla; F Spaccavento; S Pece; E Jirillo; S Antonaci
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.